## Risk Assessment Form (3) Must be completed before experimentation.

Student's Name(s) Catherine Kim
Title of Project Co-administration of Atorvastatin Blocks CYP3A4: Exacerbated Risk of Interstitial Lung
Disease
To be completed by the Student Researcher(s) in collaboration with Designated Supervisor/Qualified Scientists (All questions must be answered; additional page(s) may be attached.)
<ol> <li>List all hazardous chemicals, activities, or devices that will be used; identify microorganisms exempt from pre-approval (see Potentially Hazardous Biological Agent rules).</li> </ol>
No hazardous chemicals, activities, or devices will be used for this study.
2. Identify and assess the risks involved in this project.
Because all experimentation will be done computationally, this study will pose no risk.
3. Describe the safety precautions and procedures that will be used to reduce the risks.
Safety precautions and procedures will not be necessary for this study.
4. Describe the disposal procedures that will be used (when applicable).
Disposal procedures will not be necessary for this study.
5. List the source(s) of safety information.
Because all experimentation will be done computationally, no source of safety information will be needed.
To be completed and signed by the Designated Supervisor (or Qualified Scientist, when applicable): I agree with the risk assessment and safety precautions and procedures described above. I certify that I have reviewed the Research Plan/Project Summary and will provide direct supervision.  Digitally signed by Nicholas Tatonetti
Nicholas Tatonetti
Designated Supervisor's Printed Name Signature / / Date of Review (mm/dd/yy)
Associate Professor / Columbia University 212-305-9104 / nick.tatonetti@columbia.edu
Position & Institution Phone or email contact information
10+ years of research experience in Biomedical Informatics and Computational Biology, Ph.D. in Biomedical Informatics
Experience/Training as relates to the student's area of research